8 completed. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
Follow Aspergillosis: new trials by email Literature Review of Aspergillosis trials Research Report on Aspergillosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma Voriconazole Inhalation Powder, Placebo - Asthma | Phase 1 | Completed | TFF Pharmaceuticals, Inc. | 17 | 2020-11-15 | 2021-11-18 |
| Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects Voriconazole inhaled, oral voriconazole - Allergic Bronchopulmonary Aspergillosis | Phase 1 | Completed | Zambon SpA | 58 | 2020-02-11 | 2021-11-15 |
| Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects Voriconazole Inhalation Powder, Placebo - Healthy | Phase 1 | Completed | TFF Pharmaceuticals, Inc. | 65 | 2019-11-22 | 2021-05-06 |
| Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study) Amphotericin B Liposomal 50 MG, Placebo - Invasive Pulmonary Aspergillosis | Phase 1 | Completed | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 13 | 2019-10-18 | 2023-06-15 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945 PC945 - single doses, Placebo - single doses, PC945 - repeat doses - Aspergillosis | Phase 1 | Completed | Pulmocide Ltd | 29 | 2017-10-23 | 2018-05-01 |
| Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg - Aspergillus Infections, Candida Infections | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2015-09-01 | 2020-03-18 |
| Voriconazole to Prevent Systemic Fungal Infections in Children Voriconazole - Aspergillosis, Candidiasis | Phase 1 | Completed | National Cancer Institute (NCI) | 48 | 2000-06-01 | 2008-03-04 |
| Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia FK463 - Fever, Mycoses | Phase 1 | Completed | National Cancer Institute (NCI) | 120 | 1998-10-01 | 2008-03-04 |
Mycoses (5) · Asthma (3) · Candidiasis (3) · Fungemia (2) · Pulmonary Aspergillosis (2) · Respiratory Aspiration (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Fever (1) · Invasive Pulmonary Aspergillosis (1) · Neutropenia (1)
Bacterial Infections and Mycoses (8) · Infections (8) · Lung Diseases (5) · Respiratory Tract Diseases (5) · Lung Diseases, Fungal (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bronchial Diseases (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Invasive Fungal Infections (3) · Lung Diseases, Obstructive (3) · Mycoses (3) · Respiratory Hypersensitivity (3)
Voriconazole (3) · Amphotericin B (1) · Micafungin (1) · liposomal amphotericin B (1)
National Cancer Institute (NCI) (2) · TFF Pharmaceuticals, Inc. (2) · Chong Kun Dang Pharmaceutical (1) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (1) · Pulmocide Ltd (1) · Zambon SpA (1)
United Kingdom (2) · United States (2) · Australia (1) · Canada (1) · South Korea (1) · Spain (1)
Dale Christensen, PhD (2) · Muna Albayaty, MBChB, FFPM, MSc (1) · Sonsoles Sancho (1) · Sukh Dave Singh, Prof, MD, (1)
2015 (1), 2019 (1)